Coherus BioSciences, Inc. (CHRS)

Market Cap	129.80M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
Shares Out	115.90M
EPS (ttm)	0.25
PE Ratio	4.50
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,009,319
Open	1.030
Previous Close	1.010
Day's Range	1.020 - 1.130
52-Week Range	0.660 - 2.430
Beta	1.01
Analysts	Strong Buy
Price Target	5.38 (+380.36%)
Earnings Date	May 8, 2025

About CHRS

Coherus BioSciences, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 m...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2014
• Employees: 228
• Stock Exchange: NASDAQ
• Ticker Symbol: CHRS
• Website: https://www.coherus.com

Analyst Forecast

According to 4 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price forecast is $5.38, which is an increase of 380.36% from the latest price.

Price Target

$5.38

(380.36% upside)

Analyst Consensus: Strong Buy